Health related quality of life (HRQOL) focuses on the impact of health on a person’s ability to live a fulfilling life. HRQOL instruments are widely used worldwide to monitor population health as well as evaluate new medical innovations. Our research in this theme focuses on three areas. First, we conduct methodological research with the primary aim to better assess people’s preference in health. Second, we use observational and experimental data with quality of life information to answer specific research questions. Third, we include health and quality of life outcomes measures in clinical trials to evaluate the cost-effectiveness of new innovations and treatments [link to theme one - EE alongside trials]. The main funding bodies for our research in this stream are the National Institute for Health Research (NIHR) and the EuroQol Research Foundation.

Ongoing projects

1. Exploring the variance of EQ-5D-5L index in patients with chronic conditions in England
2. Generating of an EQ-5D-5L social value set for the Mexican Population

References to our published papers:

Voormolen DC, Polinder S, von Steinbuechel N, Feng Y, Wilson L, Oppe M, Haagsma JA, Åkerlund C et al. (2020). Health-related quality of life after traumatic brain injury: deriving value sets for the QOLIBRI-OS for Italy, The Netherlands and The United Kingdom. Quality of Life Research 10.1007/s11136-020-02583-6

Feng Y, Devlin N, Bateman A, Zamora B, Parkin D (2019). The Distribution of the EQ-5D-5L Profiles and Values in Three Patient Groups. Value in Health vol. 22, (3) 355-361. 10.1016/j.jval.2018.08.012

Mulhern B, Feng Y, Shah K, Janssen MF, Herdman M, van Hout B, Devlin N (2018). Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets. PharmacoEconomics vol. 36, (6) 699-713. 10.1007/s40273-018-0628-3

Feng Y, Hole AR, Karimi M, Tsuchiya A, van Hout B (2018). An exploration of the non-iterative time trade-off method to value health states. Health Economics vol. 27, (8) 1247-1263. 10.1002/hec.3773

Feng Y, Herdman M, van Nooten F, Cleeland C, Parkin D, Ikeda S, Igarashi A, Devlin NJ (2017). An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Quality of Life Research vol. 26, (8) 2067-2078. 10.1007/s11136-017-1541-5

Cole A, Shah K, Mulhern B, Feng Y, Devlin N (2017). Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment. The European Journal of Health Economics vol. 19, (4) 595-605. 10.1007/s10198-017-0905-7

Feng Y, Devlin NJ, Shah KK, Mulhern B, van Hout B (2017). New methods for modelling EQ-5D-5L value sets: An application to English data. Health Economics vol. 27, (1) 23-38. 10.1002/hec.3560

Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B (2017). Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics vol. 27, (1) 7-22.  10.1002/hec.3564

Parkin D, Devlin N, Feng Y (2016). What Determines the Shape of an EQ-5D Index Distribution?. Medical Decision Making vol. 36, (8) 941-951. 10.1177/0272989X16645581

Kent S, Haynes R, Hopewell J, Parish S, Gray A, Landray M J, Collins R, Armitage J, Mihaylova B on behalf of the HPS2-THRIVE Collaborative Group (2016). The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes; 9:348-354. 10.1161/CIRCOUTCOMES.115.002592

Feng Y, Devlin N, Herdman M (2015). Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?. Health and Quality of Life Outcomes vol. 13, (1) Article 171. 10.1186/s12955-015-0356-8 

Alva M, Gray A, Mihaylova B, Clarke P (2014). The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Economics; 23(4): 487-500. 10.1186/1745-6215-12-s1-a64

Mihaylova B, Pitman R, Tincello D, van der Vaart H, Tunn R, Timlin L, Quail D, Johns A, Sculpher M (2010). Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study. Value in Health;13(5):565-72. 10.1111/j.1524-4733.2010.00729.x